AI could help spot rare metabolic diseases in newborns
NCT ID NCT07368504
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This trial will test an artificial intelligence system designed to interpret routine newborn screening tests for inherited metabolic disorders. Researchers will compare the AI's accuracy to standard manual review by trained staff. The study plans to include 200,000 newborns in China, with the goal of improving screening consistency and reducing errors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- artificial intelligence-based interpretation system
- What this could lead to
- If successful, this AI system could make newborn screening for inherited metabolic disorders faster, more accurate, and more consistent across different labs.
- What could go wrong
- This is a validation study, not a treatment trial. The AI may not perform better than standard manual review, and results may not apply to populations outside China.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INHERITED METABOLIC DISORDERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.